have led investments in more than 50 companies and have an established track record of working closely with management teams in early and growth stage enterprises. These private and public companies have achieved substantial clinical and commercial success in their industry segments and have generated superior investment returns. In addition, the partners have significant biomedical and life science industry operating experience, and extensive research training from premier institutions including Harvard Medical School and UCSF Medical School.

Notable investments include Aveo Pharmaceuticals (NASDAQ: AVEO), Complete Genomics (NASDAQ: GNOM), Gloucester Pharmaceuticals (NASDAQ: CELG acquired), Healtheon (NASDAQ: WBMD merged), Idun Pharmaceuticals (NYSE: PFE acquired), Intuitive Surgical (NASDAQ: ISRG), Millennium Pharmaceuticals (Takeda Pharmaceutical acquired), Novacept (NASDAQ: HOLX acquired), Opus Medical (NASDAQ: ARTC acquired), Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ: SNMX), SurgRx (NYSE: JNJ acquired), Tercica (NYSE: IPN acquired), and Visiogen (NYSE: ABT acquired).